CannaVcell Sciences Inc. (CSE:CNVC) (“CannaVcell”) announced last Thursday, the first production of Cannabis cells in suspension, with a cannabinoid profile identical to that of the original cannabis plant – without the need to grown the plant itself. The achievement was possible using the breakthrough and patented BioHarvest’s technology (CannaVcell is the worldwide exclusive licensee of the technology for cannabis application). (See NR: www.cannavcell.com).

cannavcell


Figure 1 presents identical THCA and CBDA profiles for cannabis cells grown in liquid suspension as those found in actual cannabis flowers.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_006full.jpg

cannavcell

Figure 2 shows Cannabis cells powder that was produced in a small scale bioreactor (true picture).

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_005full.jpg

The Bioharvest technology, called biofarming, mirrors nature without any solvent extraction, genetic modification or synthetic molecular processing. In regard to Cannabis, biofarming end result is a cannabis powder with the identical composition of cannabinoids as those found in the cannabis plant. The original plant is used only once to collect its cannabis cells with the active ingredients that are subsequently perpetually reproduced with the same quality and consistency.

Dr. Yochi Hagay, CTO of BioHarvest. Dr. Hagay added, “We are the first company in the world that has been able to grow cannabis cells that produce six (6) different types of cannabinoids THCA, THC, CBDA, CBD, CBN, CBC, all of which are identical to the cannabinoids produced in the relevant Cannabis flower.”

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv2.jpg

COPY/PASTE REGISTRATION LINK: https://attendee.gotowebinar.com/register/8500294009813134092

Dr. Zaki Rakib, Co-Founder & CEO: “This achievement marks a turning point in the Cannabis Community. The revolution is here, is now! I invite the public and the Cannabis Industry, to joint me for a live webinar this Wednesday October 2nd, 2019 at 8:00 AM Pacific Daylight Time.”

About Canna-V-Cell Sciences Inc.

Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell’s objective is to become the lead- ing supplier of Cannabis for both the medicinal and recreational legal use.

Canna-V-Cell Sciences Inc.
Dr. Zaki Rakib
Co-Founder & CEO

For further info, please contact: Email: inquiries@cannavcellsciences.ca Local: 604.373.4774 Toll Free: 833.727.4774

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv4.jpg

Click here to connect with Canna-V-Cell Sciences Inc. (CSE:CNVC) for an Investor Presentation.

Source

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less